ArticleBMC complementary medicine and therapies2026
The protective effects of naringin against cisplatin-induced pulmonary toxicity in rats: Insights into the modulation of ER stress and SIRT1/Nrf2 pathway.
Article in BMC complementary medicine and therapies, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Citrus flavonoids mitigate the cisplatin-induced ovarian toxicity via dual modulation of Nrf2/HO-1 pathway and NF-κB axis.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundCisplatin (CIS) is a chemotherapeutic agent which is frequently utilised in the treatment of ovarian, breast, testicular and lung cancer. Nevertheless, the potential for severe and irreversible toxicity to the lungs restricts its utilisation. Naringin (NRG), a flavanone glycoside found in significant quantities in citrus fruits, has been demonstrated to exert protective effects against oxidative tissue damage. The present study aimed to assess the protective effect of NRG against CIS-induced pulmonary toxicity.
methodsThe administration of NRG (50 and 100 mg/kg) was conducted orally over a period of seven days. CIS (7.5 mg/kg, IP) was administered on day 2 to rats, and lung samples were collected on day 8.
resultsThe CIS application induced lipid peroxidation (LPO), inflammation, and endoplasmic reticulum stress (ERS) in the lung, resulting in the emergence of histopathological findings. However, the administration of NRG was found to be capable of preventing lung injury by suppressing LPO, inflammation and ERS levels in a dose-dependent manner. Furthermore, the suppression of CIS-induced sirtuin1(SIRT1)/nuclear factor-erythroid 2-related factor 2 (Nrf2)/heme oxygenase-1 (HO-1) signaling was abolished by NRG supplementation.
conclusionsThe present study has shown, for the first time, that NRG has a potential for protection against lung injury by modulating SIRT1/Nrf2/HO-1 signalling in the context of CIS-induced lung injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.